DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Information source: Virginia Commonwealth University
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Non-Hodgkin's Lymphoma; Leukemia; Multiple Myeloma; Acute Myeloid Leukemia; Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome

Intervention: thymoglobulin (Biological); thymoglobulin (Biological)

Phase: Phase 2

Status: Recruiting

Sponsored by: Virginia Commonwealth University

Official(s) and/or principal investigator(s):
Amir Toor, MD, Principal Investigator, Affiliation: Massey Cancer Center, VCU

Overall contact:
Amir A. Toor, MD, Phone: 804-828-4360, Email: atoor@mcvh-vcu.edu

Summary

One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.

Clinical Details

Official title: Reduced Intensity Myeloablative Total Body Irradiation and Thymoglobulin Followed by Allogeneic Peripheral Blood Stem Cell Transplantation

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: The primary endpoint of the study is a comparison of functional immune reconstitution at 6-9 months following transplant as measured by antibody response to vaccination with inactivated Hepatitis A or B vaccine.

Secondary outcome: Engraftment of donor hematopoietic stem cells, as measured by neutrophil and platelet counts

Detailed description: This randomized phase II trial studies how well giving low dose total-body irradiation (TBI) with anti-thymocyte globulin followed by donor peripheral blood stem cell transplant (PBSCT) works in treating patients with hematologic malignancies. Giving reduced intensity total-body irradiation and anti-thymocyte globulin before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving total-body irradiation together with antithymocyte globulin before transplant may stop this from happening.

Eligibility

Minimum age: 40 Years. Maximum age: 70 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with hematological malignancies for which allogeneic stem cell

transplantation indicated including non-Hodgkin lymphoma (NHL), multiple myeloma (MM), acute myeloid leukemia (AML), Hodgkin lymphoma (HD), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS)

- Patients with HLA compatible related or unrelated stem cell donor, willing and able

to serve as an allogenic HSC donor. Unrelated donors have to be matched at HLA-A, B, C and DRB1 loci. A single locus mismatch will be tolerated in the event a more closely matched donor is not available.

- Patients age >/=40 to

- Patients between 18 and 40 years of age will be eligible only if they have

co-morbidities precluding conventional allogeneic transplantation with full intensity myeloablative conditioning

- Adequate cardiac, pulmonary, renal and hepatic function for transplant

- Negative serology for HIV

- Negative serum pregnancy test

- Patients who have received therapeutic radiation to a localized field will be

eligible, provided critical structure tolerance doses have not been exceeded

- Patients who have had prior myeloablative autologous transplant will be eligible

Exclusion Criteria:

- Evidence of uncontrolled viral, fungal, bacterial infection

- Evidence of active meningeal or CNS disease

- Prior therapy with rabbit ATG, prior treatment with equine ATG is allowed if more

than 3 months ago

- Breast feeding mothers are excluded

Locations and Contacts

Amir A. Toor, MD, Phone: 804-828-4360, Email: atoor@mcvh-vcu.edu

Massey Cancer Center/Virginia Commonwealth University, Richmond, Virginia 23298-0037, United States; Recruiting
Amir A. Toor, MD, Phone: 804-828-4360, Email: atoor@mcvh-vcu.edu
Catherine T. Roberts, PhD, Phone: 804-828-1292, Email: croberts2@vcu.edu
Amir A. Toor, MD, Principal Investigator
Additional Information

VCU Massey Cancer Center

Starting date: July 2008
Last updated: January 29, 2013

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012